DMARDs in the treatment of rheumatoid arthritis: Current agents and future developments

International Journal of Clinical Practice

Volumn 54, Issue 4, 2000, Pages 243-249

  Simon, Lee S ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMINOGLYCOSIDE; ANTIMALARIAL AGENT; ANTIRHEUMATIC AGENT; AURANOFIN; AUROTHIOMALATE; AZATHIOPRINE; CALCIUM CHANNEL BLOCKING AGENT; CEPHALOSPORIN; CHLOROQUINE; CYCLOSPORIN; ETANERCEPT; FUROSEMIDE; GOLD; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; PENICILLAMINE; SALAZOSULFAPYRIDINE;

ABDOMINAL PAIN; ALOPECIA; APLASTIC ANEMIA; AUTOIMMUNE DISEASE; BONE MARROW SUPPRESSION; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DYSPEPSIA; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INFECTION; LEUKOPENIA; LIVER INJURY; MOUTH ULCER; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; PANCREATITIS; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; PRURITUS; RASH; RETINA INJURY; REVIEW; RHEUMATOID ARTHRITIS; THROMBOCYTOPENIA; VERTIGO;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIMALARIALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AURANOFIN; AZATHIOPRINE; CYCLOSPORINS; DRUG THERAPY, COMBINATION; GOLD SODIUM THIOMALATE; HUMANS; ISOXAZOLES; METHOTREXATE; PENICILLAMINE; TREATMENT OUTCOME;

EID: 0034068820     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Pincus T. Long-term outcomes in rheumatoid arthritis. Br J Rheumatol 1995; 34(suppl 2): 59-73.
2. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 1996; 39: 713-722.
3. Kirwan JR. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med 1995; 333: 142-146.
4. Pincus T, Marcum SB. Callahan LF. Long-term drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second-line drugs and prednisone. J Rheumatol 1992; 19: 1885-1894.
5. Cronstein BN. Methotrexate and its mechanism of action. Arthritis Rheum 1996; 39: 1951-1965.
6. Bannwarth B, Péhourcq F, Schaeverbeke T, Dehais J. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin Pharmacokinet 1996; 30: 194-10.
7. Williams HJ, Willkens RF, Samuelson CO Jr et al. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum 1985; 28: 721-730.
8. Andersen PA, West SG, O'Dell JR et al. Weekly pulse methotrexate in rheumatoid arthritis: clinical and immunologic effects in a randomized, double-blind study. Ann Intern Med 1985; 103: 489-496.
9. Felson DT, Anderson JJ, Meenan RF. Use of short-term efficacy/toxicity trade-offs to select second-line drugs in rheumatoid arthritis: a meta-analysis of published clinical trials. Arthritis Rheum 1992; 35: 1117-1125.
10. Alarcón GS, López-Méndez A, Walter J et al. Radiographic evidence of disease progression in methotrexate treated and nonmethotrexate disease-modifying antirheumatic drug treated rheumatoid arthritis patients: a meta-analysis. J Rheum 1992; 19: 1868-1873.
11. Rau R, Herborn G, Menninger H, Blechschmidt J. Comparison of intramuscular methotrexate and gold sodium thiomalate in the treatment of early erosive rheumatoid arthritis: 12 month data of a double-blind parallel study of 174 patients. Br J Rheumatol 1997; 36: 345-352.
12. Weinblatt ME, Kaplan H, Germain BF et al. Methotrexate in rheumatoid arthritis: a 5-year prospective multicenter study. Arthritis Rheum 1994; 37: 1492-1498.
13. Bologna C, Viu P, Picot M-C et al. Long-term follow-up of 453 rheumatoid arthritis patients treated with methotrexate: an open, retrospective, observational study. Br J Rheumatol 1997; 36: 535-540.
14. Gardner G, Furst DE. Disease-modifying antirheumatic drugs: potential effects in older patients. Drugs Aging 1995; 7: 420-437.
15. Hilliquin P, Renoux M, Perrot S et al. Occurrence of pulmonary complications during methotrexate therapy in rheumatoid arthritis. Br J Rheumatol 1996; 35:41-45.
16. Kremer JM, Alarcón GS, Lightfoot RW Jr et al. Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994; 37: 316-328.
17. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for monitoring drug therapy in rheumatoid arthritis. Arthritis Rheum 1996; 39: 723-731.
18. Rynes RI. Antimalarials. In: Dixon JS, Furst DE, Eds. Second-line agents in the treatment of rheumatic diseases. New York: Marcel Dekker, 1992; 245-266.
19. The HERA Study Group. A randomized trial of hydroxychloroquine in early rheumatoid arthritis. The HERA study. Am J Med 1996; 98: 156-168.
20. Davis MJ, Dawes PT, Fowler PD et al. Should disease-modifying agents be used in mild rheumatoid arthritis? Br J Rheumatol 1991; 30: 451-454.
21. Rynes RI. Antimalarial drugs in the treatment of rheumatological diseases. Br J Rheumatol 1997; 36: 799-805.
22. Levy GD, Munz SJ, Paschal J et al. Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice. Arthritis Rheum 1997; 40: 1482-1486.
23. Rains CP, Noble S, Faulds D. Sulfasalazine: a review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis. Drugs 1995; 50: 137-156.
24. Ebringer R, Ahern M, Thomas D et al. Sulphasalazine in early rheumatoid arthritis. The Australian Multicentre Clinical Trial Group. J Rheumatol 1992; 19: 1672-1677.
25. Hannonen P, Möttönen, Hakola M, Oka M. Sulfasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, placebo-controlled study. Arthritis Rheum 1993; 36: 1501-1509.
26. Capell HA, Torley H. Gold therapy: a choice in the 1990s. In: Dixon JS, Furst DE, Eds. Second-line agents in the treatment of rheumatic diseases. New York: Marcel Dekker, 1992; 181-202.
27. Ward JR, Williams HJ, Egger MJ et al. Comparison of auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis, a controlled clinical trial. Arthritis Rheum 1983; 26: 1303-1315.
28. Kean WF, Hart L, Buchanan WW. Auranofin. Br J Rheumatol 1997; 36: 560-572.
29. Munro R, Capell HA. Penicillamine. Br J Rheumatol 1997; 36: 104-109.
30. Capell HA, Marabani M, Madhok R et al. Degree and extent of response to sulphasalazine or penicillamine therapy for rheumatoid arthritis: results from a routine clinical environment over a two-year period. Q J Med 1990; 75: 335-344.
31. Eberhardt K, Rydgren L, Fex E et al. D-penicillamine in early rheumatoid arthritis: experience from a 2-year double blind placebo controlled study. Clin Exp Rheumatol 1996; 14: 625-631.
32. Porter DR, McInnes I, Hunter J, Capell HA. Outcome of second line therapy in rheumatoid arthritis. Ann Rheum Dis 1994; 53: 812-815.
33. McKendry RJR. Purine analogs. In: Dixon JS, Furst DE, Eds. Second-line agents in the treatment of rheumatic diseases. New York: Marcel Dekker, 1992; 223-243.
34. Woodland J, Chaput de Saintonge DM, Evans SJW et al. Azathioprine in rheumatoid arthritis: double-blind study of full versus half doses versus placebo. Ann Rheum Dis 1981; 40: 355-359.
35. DeSilva M, Hazleman BL. Long-term azathioprine in rheumatoid arthritis: a double-blind study. Ann Rheum Dis 1981; 40: 560-563.
36. Currey HLG, Harris J, Mason RM et al. Comparison of azathioprine, cyclophosphamide, and gold in treatment of rheumatoid arthritis. BMJ 1974; 3: 763-766.
37. Singh G, Fries JF, Spitz P, Williams CA. Toxic effects of azathioprine in rheumatoid arthritis: a national post-marketing perspective. Arthritis Rheum 1989; 32: 837-843.
38. Clipstone NA, Crabtree GR. Calcineurin is a key signaling enzyme in T lymphocyte activation and the target of the immunosuppressive drugs cyclosporine and FK506. Ann NY Acad Sci 1993; 696: 20-30.
39. Pasero G, Priolo F, Marubini E et al. Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin A. Arthritis Rheum 1996; 39: 1006-1015.
40. Davis JP, Cain GA, Pitts WJ et al. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry 1996; 35: 1270-1273.
41. Mladenovic V, Domljan Z, Rozman B et al. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis: results of a randomized, placebo-controlled, phase II study. Arthritis Rheum 1995; 38: 1595-1603.
42. Strand V, Cohen S, Schiff M et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 1999; 159: 2542-2550.
43. Smolen JS, Kalden, JR, Scott DL et al. Efficacy and safety of leflunomide compared to placebo and sulphasalazine in active rheumatoid arthritis. Lancet 1999; 353: 259-266.
44. Williams HJ, Ward JR, Reading JC et al. Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum 1992; 35: 259-269.
45. Tugwell P, Pincus T, Yocum D et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med 1995; 333: 137-141.
46. Willkens RF, Stablein D. Combination treatment of rheumatoid arthritis using azathioprine and methotrexate: a 48 week controlled clinical trial. J Rheumatol 1996; 23(suppl 44): 64-68.
47. Faarvang KL, Egsmose C, Kryger P et al. Hydroxychloroquine and sulphasalazine alone and in combination in rheumatoid arthritis: a randomised double blind trial. Ann Rheum Dis 1993; 52: 711-715.
48. Bendix G, Bjelle A. Adding low-dose cyclosporin A to parenteral gold therapy in rheumatoid arthritis: a double-blind placebo-controlled study. Br J Rheumatol 1996; 35: 1142-1149.
49. O'Dell JR, Haire CE, Eriskson N et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996; 334: 1287-1291.
50. Weinblatt ME, Kremer JM, Coblyn JS et al. Efficacy, safety and pharmacokinetics of the combination of methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 1999; 42: 1322-1328.
51. Moreland LW, Baumgartner SW, Schiff MH et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337: 141-147.
52. Weinblatt ME, Kremer JM, Bankhurst AD et al. A trial of etanercept, a recombination tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253-259.
53. Felson DT, Anderson JJ, Meenan RF. The efficacy and toxicity of combination therapy in rheumatoid arthritis: a meta-analysis. Arthritis Rheum 1994; 37: 1487-1491.